Biogen vs Krystal Biotech
Biogen (BIIB) and Krystal Biotech (KRYS) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $36.9B
- Last close
- $249.59
- 12 months
- +48.4%
- Market value
- $9.15B
- Last close
- $308.89
- 12 months
- +51.3%
At a glance
- The biggest part of Biogen's revenue is TYSABRI, 17% of the total in its last annual report.
- By market value, Biogen ($36.9B) is about 4.0 times Krystal Biotech ($9.2B).
- Over the last 12 months Biogen's share price moved +48.4% and Krystal Biotech's +51.3%; against the S&P 500 that is +42.7 points and +45.5 points.
- In their last fiscal years Biogen kept 13.1% of revenue as net income and Krystal Biotech 52.6%.
- In the last 90 days insiders reported 0 open-market purchases at Biogen and 0 at Krystal Biotech; members of Congress disclosed 2 trades in Biogen and 0 in Krystal Biotech.
- Next results: Biogen Feb 4, 2027, Krystal Biotech Feb 15, 2027.
How each one makes money: Biogen revenue
Share prices on one chart
Biogen and Krystal Biotech, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Biogen BIIBNASDAQ · Biotechnology | Krystal Biotech KRYSNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $36.9B | $9.15B |
| Revenue, last fiscal year | $9.89B | $389M |
| Net income, last fiscal year | $1.29B | $205M |
| Net marginNet income as a share of revenue | 13.1% | 52.6% |
| Free cash flow | $2.05B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Biogen against
Common questions
How is Biogen different from Krystal Biotech?
Biogen (BIIB) is in Biotechnology on NASDAQ, with $9.89B of revenue in its last fiscal year and a net margin of 13.1%. Krystal Biotech (KRYS) is in Biotechnology on NASDAQ, with $389M of revenue in its last fiscal year and a net margin of 52.6%. The biggest part of Biogen's revenue is TYSABRI, 17% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Biogen and Krystal Biotech compare in size?
Biogen has the larger market value: Biogen $36.9B and Krystal Biotech $9.15B, at the last close.
Whose share price rose more over the last 12 months, BIIB or KRYS?
Over the last 12 months Biogen moved +48.4% and Krystal Biotech +51.3%. Past price moves say nothing about the future.
Which has had more insider buying, Biogen or Krystal Biotech?
Since 2006, Biogen insiders reported 34 open-market purchases against 11 for Krystal Biotech. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BIIB or KRYS?
In the last 12 months, members of Congress disclosed 9 trades in Biogen (BIIB) and 0 in Krystal Biotech (KRYS).
When did insiders last buy BIIB and KRYS?
Biogen: Feb 18, 2026. Krystal Biotech: Oct 18, 2018.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Biogen pageKrystal Biotech pageRare insider trades this weekAll comparisons
https://oqro.io/compare/biib-vs-krys







